# Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Source: https://onco.cc/trials/nct04417530/  
OnCo record `nct04417530` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Belzupacap sarotalocan run by Aura Biosciences, completed.

## Summary

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma is a phase 2 interventional study registered as NCT04417530 by Aura Biosciences, with 22 participants enrolled, started 2020-08-05. Conditions recorded: Uveal Melanoma, Ocular Melanoma and Choroidal Melanoma. Interventions recorded: AU-011, Suprachoroidal Microinjector and PDT Laser.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04417530
- Phase: 2
- Setting: A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
- Sponsor: Aura Biosciences
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT04417530: https://clinicaltrials.gov/study/NCT04417530

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Belzupacap sarotalocan](https://onco.cc/drugs/belzupacap-sarotalocan/)
- companies: [Aura Biosciences](https://onco.cc/companies/aura-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct04417530.json